- Report
- March 2024
- 189 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Clinical Trials
- April 2024
- 450 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- April 2018
- 168 Pages
Global
From €1321EUR$1,375USD£1,137GBP
€2641EUR$2,750USD£2,274GBP
- Report
- February 2023
- 30 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2641EUR$2,750USD£2,274GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3122EUR$3,250USD£2,687GBP
- Drug Pipelines
- January 2018
- 61 Pages
Global
From €9605EUR$10,000USD£8,269GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
Lynparza (olaparib) is a poly ADP-ribose polymerase (PARP) inhibitor used to treat ovarian cancer. It is used in combination with other drugs to treat advanced ovarian cancer in women who have already been treated with chemotherapy. It works by blocking the action of an enzyme called PARP, which helps cancer cells repair themselves and survive. This makes it harder for the cancer cells to survive and grow. Lynparza is approved by the US Food and Drug Administration (FDA) for the treatment of advanced ovarian cancer.
Lynparza is marketed by AstraZeneca and Merck & Co. It is also available in generic form from several other companies. Other PARP inhibitors used to treat ovarian cancer include Rubraca (rucaparib), Zejula (niraparib), and Talzenna (talazoparib).
Companies in the Lynparza market include AstraZeneca, Merck & Co., Mylan, Teva Pharmaceuticals, Accord Healthcare, and Sun Pharmaceuticals. Show Less Read more
